NEW
Stock Screener with Intrinsic Value
Vertex Pharmaceuticals Incorporated (VRTX)
Last Price$409.9(0.5%)
Market Cap$105.0B
LTM Free Cash Flow
($1,163.8M)
Reverse DCF (Implied FCF growth)
(100.0%)
3Y Free Cash Flow CAGR
N/A
LTM Revenue
$10.6B
Reverse DCF (Implied Revenue growth)
36.8%
at normalized FCF margin 3.1%
3Y Revenue CAGR
14.2%
VRTX Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
VRTX Free Cash Flow
Crunching data... Almost there!
VRTX Growth
Crunching data... Almost there!
VRTX vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for VRTX
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Vertex Pharmaceuticals Incorporated Reverse DCF (discounted cash flow) valuation?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at (100.0%).
What is Vertex Pharmaceuticals Incorporated WACC?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Weighted Average Cost of Capital (WACC) is approximately 6.9%.
What is Vertex Pharmaceuticals Incorporated Free Cash Flow?
As of Sep 30, 2024, Vertex Pharmaceuticals Incorporated's Free Cash Flow is ($1,163.8M).